Ruxolitinib Beats Standard Therapy at Tamping Down Resistant Graft-Versus-Host Disease Ruxolitinib Beats Standard Therapy at Tamping Down Resistant Graft-Versus-Host Disease
When GVHD is resistant to standard glucocorticoid therapy in patients who have received an allogeneic stem-cell transplant, ruxolitinib performs better than other treatment options, according to results of REACH2.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Hematology | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants